13F Holdings
中文EN

HRMY Harmony Biosciences Holdings, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1802665 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY19.8%
TTM net income YoY-3.8%
TTM EPS YoY-4.7%
Revenue 3-yr CAGR22.2%
Net income 3-yr CAGR5.8%

Margins

Gross margin74.0%
Operating margin22.2%
Net margin18.1%
FCF margin—
EBITDA margin—

Returns

ROE18.7%
ROA13.3%
ROIC (approx.)36.1%
Asset turnover0.74x

Leverage & solvency

Liabilities / assets27.5%
Debt / equity0.14x
Current ratio3.44x
Interest coverage16.99x

Cash quality & payout

Operating cash flow / net income1.81x
Accruals ratio-10.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$868.45M$714.73M$582.02M$437.86M$305.44M
Cost of revenue$198.34M$156.81M$121.24M$83.48M$55.52M
Gross profit$670.11M$557.92M$460.79M$354.37M$249.92M
R&D expense$189.59M$145.82M$76.06M$70.89M$30.37M
SG&A expense$152.54M$110.35M$95.29M$84.02M$63.91M
Operating income$208.47M$190.83M$192.03M$120.19M$87.53M
Interest expense$14.65M$17.50M$23.76M$18.80M$24.19M
Pretax income$215.06M$191.80M$173.40M$104.69M$37.43M
Income tax$56.38M$46.31M$44.54M-$76.78M$2.83M
Net income$158.69M$145.49M$128.85M$181.47M$34.60M
EBITDA—$191.09M$192.54M$120.61M$87.94M
EPS (basic)2.762.562.173.070.60
EPS (diluted)2.712.512.132.970.58
Weighted avg. shares (diluted)58.54M57.87M60.37M61.10M59.21M
Balance sheet
Cash & equivalents$752.50M$453.27M$311.93M$244.53M$235.06M
Short-term investments$22.84M$14.19M$41.80M$79.33M—
Receivables$96.79M$83.03M$74.14M$54.74M$34.84M
Inventory$5.36M$7.20M$5.36M$4.30M$4.43M
Current assets$907.01M$579.25M$451.07M$400.29M$284.44M
PP&E, net—$1.26M$371,000$573,000$820,000
Intangibles$89.42M$113.26M$137.11M$160.95M$143.92M
Total assets$1.27B$999.20M$811.45M$673.87M$433.44M
Current liabilities$252.13M$175.08M$163.78M$78.88M$53.77M
Short-term debt$20.00M$16.25M$15.00M$2.00M$2.00M
Long-term debt$143.66M$163.02M$178.57M$189.65M$189.98M
Total debt$163.66M$179.27M$193.57M$191.65M$191.98M
Total liabilities$401.41M$340.05M$344.46M$271.03M$246.94M
Shareholders' equity$870.22M$659.15M$466.99M$402.84M$186.51M
Net debt-$588.84M-$274.00M-$118.36M-$52.89M-$43.08M
Shares outstanding57.73M57.14M56.77M59.62M58.83M
Cash flow statement
Operating cash flow$348.20M$219.82M$219.39M$144.47M$98.56M
Capital expenditure$310,000$1.15M$312,000$172,000$298,000
Free cash flow$347.89M$218.67M$219.07M$144.29M$98.26M
Investing cash flow-$39.65M-$67.48M-$46.44M-$141.83M-$100.30M
Financing cash flow-$9.05M-$11.00M-$105.55M$6.84M$7.42M
Depreciation & amortization—$267,000$514,000$419,000$416,000
Stock-based compensation$44.90M$42.60M$31.70M$26.17M$15.66M
Share buybacks——$100.00M——

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.